42065-76-9

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 73, p. 5675, 1951 DOI: 10.1021/ja01156a055

InChI:InChI=1/C3H9NO3S/c1-3(2)4-8(5,6)7/h3-4H,1-2H3,(H,5,6,7)

Upstream product

• 5080-22-8 N-isopropylhydroxyamine 
• 75-31-0 isopropylamine 
• 1795-48-8 Isopropyl isocyanate 
• 75-52-5 nitromethane 

Downstream Products

• 26118-67-2 isopropylsulfamoyl chloride 

Relevant academic research and scientific papers

Piperidyindoles as serotonin receptor ligands

A pharmaceutical compound of the formula (I) in which R1 and R2 are each hydrogen or C1-6 alkyl, R3 is —SR10, —SOR10, —SO2R10, —COR10, —CH2OH or —CONHR11, where R10 is C1-6 alkyl and R11 is hydrogen or C1-6 alkyl, R4, R5, R6 and R7 are each hydrogen or C1-6 alkyl, provided that at least one of R4, R5, R6 and R7 is C1-6 alkyl, R8 and R9 are each hydrogen, halo, C1-6 alkyl or cyano, n is 0 or 1 and m is 2 or 3, x is a (a) or (b), and y is (c) or (d), wherein R12 and R13 are each hydrogen, C1- alkyl, cyclopropyl or cyclopropyl-C1-6 alkyl; and salts thereof.

Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action

Modification of the α-carbamate substituent of isoxazoline GPIIb/IIIa (α(IIb)β3) antagonist DMP 754 (7) led to a series of α-sulfonamide and α-sulfamide diaminopropionate isoxazolinylacetamides which were found to be potent inhibitors of in vitro platelet aggregation. Aryl- and heteroaryl-α- sulfonamide groups, in conjunction with (5R)-isoxazoline (2S)- diaminopropionate stereochemistry, were found to impact a pronounced duration of antiplatelet effect in dogs, potentially due to high affinity for unactivated platelets. Isoxazolylsulfonamide 34b (DMP 802), a highly selective GPIIb/IIIa antagonist, demonstrated a prolonged duration of action after iv and po dosing and high affinity for resting and activated platelets. The prolonged antiplatelet profile of DMP 802 in dogs and the high affinity of DMP 802 for human platelets may be predictive of clinical utility as a once-daily antiplatelet agent.

1H-2,1,3-benzothiadiazine-2,2-dioxide compounds or derivatives thereof

A pharmaceutical compound having the formula: STR1 in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R1 and R2 are each hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, C1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C1-4 alkyl, or R3 and R4 together form an alkylene link of formula --(CH2)3 -- or --(CH2)4 --, or R4 and R5 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, R6 is C1-4 alkyl, C1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof.

Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands

Compounds having the formula: in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R1and R2are each hydrogen or C1-4alkyl, R3, R4and R5are each hydrogen, C1-4alkyl, optionally substituted phenyl or optionally substituted phenyl-C1-4alkyl, or R3and R4together form an alkylene link of formula -(CH2)3- or -(CH2)4-, or R4and R5together with the carbon atom to which they are attached form a C3-6cycloalkyl group, R6is C1-4alkyl, C1-4alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof, are binding to the 5-HT serotonin receptor and are useful in the treatment of CNS disorders.